Literature DB >> 11560297

Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.

V M Montori1, G L Schwartz, A B Chapman, E Boerwinkle, S T Turner.   

Abstract

OBJECTIVE: To determine whether the calculated ratio of plasma aldosterone concentration (PAC) to plasma renin activity (PRA), a proposed screening test for primary aldosteronism, provides a renin-independent measure of circulating aldosterone that is suitable to judge whether PAC is inappropriately elevated relative to PRA. SUBJECTS AND METHODS: This study consisting of 221 black and 276 white subjects with previously diagnosed essential hypertension was conducted between 1996 and 2000. Antihypertensive drugs were withdrawn for at least 4 weeks; PAC and PRA were measured while subjects were supine and then seated after 30 minutes of ambulation. The seated measurements were repeated after 4 weeks of oral diuretic therapy with hydrochlorothiazide (25 mg/d).
RESULTS: The variation in the aldosterone-renin ratio was strongly and inversely dependent on PRA (R2=0.71; P<.001). When subjects changed position from supine to seated, the increase in mean +/- SD PRA (from 1.18 +/- 1.06 to 1.31 +/- 1.19 ng x mL(-1) x h(-1); P<.001) was associated with an increase in the mean ratio (from 18.6 +/- 52.8 to 25.8 +/- 38.1 h x 10(2); P<.001), whereas the increase in mean +/- SD PRA in response to diuretic therapy (from 1.31 +/- 1.19 to 2.72 +/- 2.67 ng x mL(-1) x h(-1); P=.007) was associated with a decrease in the mean ratio (from 25.8 +/- 38.1 to 16.4 +/- 31.6 h 10(2); P<.001).
CONCLUSION: In patients with previously diagnosed essential hypertension, calculation of the aldosterone-renin ratio does not provide a renin-independent measure of circulating aldosterone that is suitable for determining whether PAC is elevated relative to PRA. Because elevation of the aldosterone-renin ratio is predominantly an indicator of low PRA, its perceived value in screening for primary aldosteronism most likely derives from additional diagnostic tests being done in patients with low-renin hypertension.

Entities:  

Mesh:

Year:  2001        PMID: 11560297     DOI: 10.4065/76.9.877

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  18 in total

1.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

2.  A patient with concurrent primary aldosteronism and Page kidney.

Authors:  Chin-Chi Kuo; Huan-Lun Hsu; Chao-Yuan Huang; Kao-Lang Liu; Vin-Cent Wu; Ching-Wei Tsai; Wei-Jie Wang
Journal:  Endocrine       Date:  2010-06-24       Impact factor: 3.633

3.  Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease.

Authors:  Wei-Guo Chen; Ting-Ting Zhou; Peng Zhou; Xiao-Wei Li; Zhun Wu; Kai-Yan Zhang; Jin-Chun Xing
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 4.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

5.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

Review 6.  Primary aldosteronism and a Texas two-step.

Authors:  Richard J Auchus
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 7.  Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness.

Authors:  Gary L Schwartz
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 8.  Functional tests for primary aldosteronism: value of captopril suppression.

Authors:  Marie-Claude Racine; Pierre Douville; Marcel Lebel
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

9.  Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism.

Authors:  Evelyn Fischer; Felix Beuschlein; Martin Bidlingmaier; Martin Reincke
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 10.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.